SecBot SecBot
PRESS-RELEASE ·Filed Apr 13, 2026

SEPN

Septerna, Inc.
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Investors should monitor enrollment progress and safety signals ahead of the late 2026/early 2027 data readout. A successful Phase 1 could de-risk the program and expand Septerna’s valuation premium, especially if SEP-479 demonstrates pharmacodynamic activity and differentiates from injectable PTH therapies.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$23.34
T+0 close · Apr 13, 2026 · via day close
Latest settled
+55.96%
T+60 · $36.40
Vs SPY
+47.03%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $23.34entry
  2. T+1 · 7mo ago +3.38%α +2.17% · $24.13
  3. T+5 · 7mo ago +15.08%α +11.79% · $26.86
  4. T+20 · 6mo ago +0.99%α −6.74% · $23.57
  5. T+60 · 4mo ago +55.96%α +47.03% · $36.40
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Septerna announced the dosing of the first participants in its Phase 1 trial of SEP-479, an oral small molecule PTH1R agonist for hypoparathyroidism. Clinical data is expected in late 2026 or early 2027. This marks a key milestone in advancing a potential first-in-class oral therapy for a rare endocrine disorder.

Key Facts

  • Septerna has initiated dosing in the Phase 1 clinical trial of SEP-479 for hypoparathyroidism.
  • The trial is a single- and multiple-ascending dose study in healthy volunteers, evaluating safety, tolerability, PK, and PD.
  • Up to 150 participants will be enrolled; data readout expected in late 2026 or early 2027.
  • SEP-479 is a potent oral small molecule agonist targeting the PTH1R receptor, aiming to provide once-daily dosing.
  • Preclinical data showed normalization of serum calcium and favorable tolerability in GLP toxicology studies.

Financial Impact

No immediate financial impact; long-term commercial potential hinges on clinical success. Hypoparathyroidism market remains underserved, with current treatments involving daily injections or high-dose supplements.

pipeline_valueR&D_progressmarket_sentiment

Risk Factors

  • Phase 1 may reveal unexpected safety, PK, or PD findings that could halt development.
  • Preclinical results may not translate to humans, particularly in disease-modifying effects.
  • Timing delays in trial completion or data readout could dampen investor enthusiasm.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3272435

US Market Status

Market Closed · Opens Wed (11h 47m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026